DGX240719P145000
- 0.45
- -0.47-51.09%
Quest Diagnostics Newsroom
Quest Diagnostics Is Maintained at Hold by Truist Securities
Quest Diagnostics Is Maintained at Hold by Truist
Quest Diagnostics Price Target Raised to $158.00/Share From $150.00 by Truist Securities
Quest Diagnostics Price Target Raised to $158.00/Share From $150.00 by Truist
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $158
Truist Financial analyst David S Macdonald maintains $Quest Diagnostics(DGX.US)$ with a hold rating, and adjusts the target price from $145 to $158.According to TipRanks data, the analyst has a
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
Truist Securities Adjusts Price Target on Quest Diagnostics to $158 From $150, Maintains Hold Rating
Quest Diagnostics (DGX) has an average outperform rating and a price target range of $136 to $165, according to analysts polled by Capital IQ.
Is Quest Diagnostics Incorporated (DGX) an Undervalued High Growth Stock?
Express News | Quest Diagnostics Inc : Leerink Partners Raises Target Price to $151 From $141
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
Quest Diagnostics to Purchase Outreach Lab Assets From Health System OhioHealth
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Express News | Quest Diagnostics Inc: Financial Details of Transaction Were Not Disclosed.
Express News | Quest Diagnostics to Acquire Outreach Laboratory Services of Ohiohealth
Express News | Quest Diagnostics Inc : Citigroup Raises to Buy From Neutral; Raises Target Price to $165 From $145
Citi Upgrades Quest Diagnostics(DGX.US) to Buy Rating, Raises Target Price to $165
Citi analyst Patrick B Donnelly upgrades $Quest Diagnostics(DGX.US)$ to a buy rating, and adjusts the target price from $145 to $165.According to TipRanks data, the analyst has a success rate of 45.7%
Citigroup Upgrades Quest Diagnostics to Buy From Neutral, Adjusts Price Target to $165 From $145
Quest Diagnostics (DGX) has an average outperform rating and a price target range of $136 to $160, according to analysts polled by Capital IQ.Price: 137.78, Change: -0.58, Percent Change: -0.42
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
Express News | Quest Diagnostics Inc : Baird Raises Target Price to $153 From $145
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1815 GMT - Quest Diagnostics' long-rumored acquisition of Life
Quest Diagnostics' LifeLabs Buy Could Boost Earnings by 4% to 5% -- Market Talk
1145 ET - Quest Diagnostics acquiring LifeLabs could be 4% to 5% accretive to its earnings in fiscal 2025, UBS analysts say, assuming the lab-test provider grows 5% annually and Quest uses a fairly eq